Scott S. Tykodi

20.9k total citations
106 papers, 3.1k citations indexed

About

Scott S. Tykodi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Scott S. Tykodi has authored 106 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 62 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Scott S. Tykodi's work include Renal cell carcinoma treatment (61 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Renal and related cancers (30 papers). Scott S. Tykodi is often cited by papers focused on Renal cell carcinoma treatment (61 papers), Cancer Immunotherapy and Biomarkers (44 papers) and Renal and related cancers (30 papers). Scott S. Tykodi collaborates with scholars based in United States, United Kingdom and Denmark. Scott S. Tykodi's co-authors include John A. Thompson, Shailender Bhatia, Edus H. Warren, David F. McDermott, Saby George, Robert J. Motzer, Stanley R. Riddell, Hans J. Hammers, Elizabeth R. Plimack and Frede Donskov and has published in prestigious journals such as Nature, Science and Journal of Clinical Oncology.

In The Last Decade

Scott S. Tykodi

103 papers receiving 3.1k citations

Peers

Scott S. Tykodi

ONCOL

PRM

IMMUN

Salvador Martín‐Algarra Spain

Suxia Luo China

Angela Märten Germany

Diego Chowell United States

Thomas Olencki United States

Shigehisa Kitano Japan

Martin Gutierrez United States

April K.S. Salama United States

Patricia Rayman United States

Salvador Martín‐Algarra Spain

Scott S. Tykodi

2.2k ×1.2

ONCOL

928 ×0.8

PRM

1.3k ×1.1

1.1k ×1.2

IMMUN

722 ×1.3

Citations per year, relative to Scott S. Tykodi Scott S. Tykodi (= 1×) peers Salvador Martín‐Algarra

Countries citing papers authored by Scott S. Tykodi

Since Specialization

Citations

This map shows the geographic impact of Scott S. Tykodi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott S. Tykodi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott S. Tykodi more than expected).

Fields of papers citing papers by Scott S. Tykodi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott S. Tykodi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott S. Tykodi. The network helps show where Scott S. Tykodi may publish in the future.

Co-authorship network of co-authors of Scott S. Tykodi

This figure shows the co-authorship network connecting the top 25 collaborators of Scott S. Tykodi. A scholar is included among the top collaborators of Scott S. Tykodi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott S. Tykodi. Scott S. Tykodi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jefferson, J. Ashley, Karin Chen, Sangeeta Hingorani, et al.. (2025). Genetic and Iatrogenic Defects in Peripheral Tolerance Associated with Anti-Nephrin Antibody-Associated Minimal Change Disease. PubMed. 5(1). 74–83.

Gouda, Mohamed A., Martin H. Voss, Hussein A. Tawbi, et al.. (2025). A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 10(5). 104536–104536. 17 indexed citations

Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2025). Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 549–549.

Gadzinski, Adam J., Petros Grivas, Scott S. Tykodi, et al.. (2024). Telemedicine for Multidisciplinary Urologic Cancer Care: A Prospective Single Institution Study. Clinical Genitourinary Cancer. 22(3). 102058–102058. 2 indexed citations

Hall, Evan, Raquibul Hannan, Jay J. Liao, et al.. (2024). Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review. Future Oncology. 20(33). 2573–2588. 4 indexed citations

Choueiri, Toni K., Todd M. Bauer, Jaime R. Merchan, et al.. (2023). LBA87 Phase II LITESPARK-003 study of belzutifan in combination with cabozantinib for advanced clear cell renal cell carcinoma (ccRCC). Annals of Oncology. 34. S1328–S1329. 9 indexed citations

Goff, Peter H., Kelsey K. Baker, Sylvia M. Lee, et al.. (2023). 610 ImmunoRad: a stratified phase II trial of image guided hypofractionated radiotherapy with concurrent nelfinavir & PD-1 inhibition in advanced melanoma, lung cancer & renal cell carcinoma. SHILAP Revista de lepidopterología. A694–A694.

Rini, Brian I., Sabina Signoretti, Toni K. Choueiri, et al.. (2022). Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(12). e005445–e005445. 42 indexed citations

George, Daniel J., David R. Spigel, Lucio Gordan, et al.. (2022). Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ Open. 12(9). e058396–e058396. 4 indexed citations

10.

McDermott, David F., Toni K. Choueiri, Scott S. Tykodi, et al.. (2022). 1453P Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003. Annals of Oncology. 33. S1208–S1209. 3 indexed citations

11.

Portuguese, Andrew J., Jordan Gauthier, Scott S. Tykodi, et al.. (2022). CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review. Bone Marrow Transplantation. 58(4). 353–359. 16 indexed citations

12.

McDermott, David F., Jae‐Lyun Lee, Georg A. Bjarnason, et al.. (2021). Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology. 39(9). 1020–1028. 90 indexed citations

13.

Figlin, Robert A., Nizar M. Tannir, Robert G. Uzzo, et al.. (2020). Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 26(10). 2327–2336. 53 indexed citations

14.

Veatch, Joshua, et al.. (2020). Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab. Journal for ImmunoTherapy of Cancer. 8(2). e001591–e001591. 8 indexed citations

15.

Diab, Adi, Michael E. Hurwitz, Nizar M. Tannir, et al.. (2017). PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Annals of Oncology. 28. v426–v427. 4 indexed citations

16.

Tykodi, Scott S., Brenda M. Sandmaier, Edus H. Warren, & John A. Thompson. (2011). Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. Expert Opinion on Biological Therapy. 11(6). 763–773. 5 indexed citations

17.

Tykodi, Scott S., Nobuharu Fujii, Nathalie Vigneron, et al.. (2008). C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research. 14(16). 5260–5269. 43 indexed citations

18.

Warren, Edus H., Nathalie Vigneron, Marc A. Gavin, et al.. (2006). An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. Science. 313(5792). 1444–1447. 160 indexed citations

19.

Warren, Edus H., Scott S. Tykodi, Makoto Murata, et al.. (2002). T-cell therapy targeting minor histocompatibility Ags for the treatment of leukemia and renal-cell carcinoma. Cytotherapy. 4(5). 441–441. 11 indexed citations

20.

Fan, Rong, Scott S. Tykodi, & Thomas J. Braciale. (2000). Recognition of a Sequestered Self Peptide by Influenza Virus-Specific CD8+ Cytolytic T Lymphocytes. The Journal of Immunology. 164(4). 1669–1680. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact